Brett A Murphy
CIK 1555034 · View on SEC EDGAR ↗
First SEC filing: Aug. 2, 2012 · Latest: Aug. 2, 2012
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Nov. 10, 2017 | GMED | S 10b5-1 | 14,551 | $35.00 | $509,285 | 35,217 Direct | -29.24% | Disposed | 152.1% (price as of 2026-08-19) |
| Nov. 9, 2017 | GMED | S 10b5-1 | 51,449 | $35.00 | $1,800,715 | 49,768 Direct | -50.83% | Disposed | 152.1% (price as of 2026-08-19) |
| Sept. 6, 2017 | GMED | S | 15,000 | $29.99 | $449,850 | 101,217 Direct | -12.91% | Disposed | 194.2% (price as of 2026-08-19) |
| Aug. 5, 2016 | GMED | S | 32,992 | $23.39 | $771,683 | 116,217 Direct | -22.11% | Disposed | 277.3% (price as of 2026-08-19) |
| Aug. 4, 2016 | GMED | S | 74,700 | $23.36 | $1,744,992 | 116,217 Direct | -39.13% | Disposed | 277.7% (price as of 2026-08-19) |
| Nov. 16, 2015 | GMED | S | 5,000 | $25.80 | $129,000 | 116,217 Direct | -4.12% | Disposed | 242.0% (price as of 2026-08-19) |
| Jan. 30, 2013 | GMED | S 10b5-1 | 31,103 | $12.87 | $400,296 | 121,217 Direct | -20.42% | Disposed | 585.6% (price as of 2026-08-19) |
| Aug. 8, 2012 | GMED | S | 16,910 | $11.16 | $188,716 | 152,320 Direct | -9.99% | Disposed | 690.7% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 2, 2018 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (40,000) | $45.64 | Feb. 2, 2028 | 40,000 | Acquired |
| Jan. 30, 2017 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (80,000) | $26.27 | Jan. 30, 2027 | 80,000 | Acquired |
| Aug. 5, 2016 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (32,992) | $2.93 | Nov. 1, 2016 | 32,992 | Disposed |
| Aug. 4, 2016 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (74,700) | $2.93 | Nov. 1, 2016 | 74,700 | Disposed |
| Jan. 25, 2016 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (60,000) | $25.52 | Jan. 25, 2026 | 60,000 | Acquired |
| July 7, 2015 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (100,000) | $25.65 | July 7, 2025 | 100,000 | Acquired |
| Jan. 20, 2015 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (50,000) | $24.10 | Jan. 20, 2025 | 50,000 | Acquired |
| Jan. 23, 2014 | GMED | Stock Option (Right to Buy Class A Common Stock | Class A Common Stock (30,000) | $23.95 | Jan. 23, 2024 | 30,000 | Acquired |
| Jan. 24, 2013 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (25,000) | $13.04 | Jan. 24, 2023 | 25,000 | Acquired |
| Aug. 29, 2012 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (10,000) | $15.34 | Aug. 29, 2022 | 10,000 | Acquired |
| Aug. 8, 2012 | GMED | Stock Option (Right to Buy Class A Common Stock [F2] | Class A Common Stock [F2] (12,307) | $10.66 | Oct. 27, 2021 | 12,307 | Acquired |
| Aug. 8, 2012 | GMED | Stock Option (Right to Buy Class A Common Stock) [F2] | Class A Common Stock [F2] (15,384) | $11.28 | April 20, 2021 | 15,384 | Acquired |
| Aug. 8, 2012 | GMED | Stock Option (Right to Buy Class A Common Stock) [F2] | Class A Common Stock [F2] (9,230) | $11.87 | June 16, 2020 | 9,230 | Acquired |
| Aug. 8, 2012 | GMED | Stock Option (Right to Buy Class A Common Stock) [F2] | Class A Common Stock [F2] (9,230) | $4.88 | Aug. 6, 2019 | 9,230 | Acquired |
| Aug. 8, 2012 | GMED | Class B Common Stock | Class A Common Stock (92,307) | — | — | 92,307 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 7 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Aug. 2, 2012 | GMED | Class A Common Stock | 76,923 | Direct |
| Aug. 2, 2012 | GMED | Class B Common Stock [F1]→ Class A Common Stock | — | Direct |
| Aug. 2, 2012 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (107,692) | 107,692 | Direct |
| Aug. 2, 2012 | GMED | Stock Option (Right to Buy Class C Common Stock) [F3]→ Class C Common Stock [F3] | — | Direct |
| Aug. 2, 2012 | GMED | Stock Option (Right to Buy Class C Common Stock) [F3]→ Class C Common Stock [F3] | — | Direct |
| Aug. 2, 2012 | GMED | Stock Option (Right to Buy Class C Common Stock) [F3]→ Class C Common Stock [F3] | — | Direct |
| Aug. 2, 2012 | GMED | Stock Option (Right to Buy Class C Common Stock) [F3]→ Class C Common Stock [F3] | — | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
GMED
EVP| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2017 | $374,290 | — | — | $666,149 | $250,000 | — | $22,365 | $1,312,804 |
| 2016 | $364,000 | — | — | $482,003 | $325,451 | — | $22,656 | $1,194,110 |
| 2015 | $333,086 | $15,787 | — | $1,220,624 | $376,323 | — | $22,634 | $1,968,454 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.